articleTop 1% cited

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

The Lancet Oncology · 2010 · Vol. 11(8) · pp. 753–762

Wendy De Roock✉(KU Leuven)Bart Claes(KU Leuven)David Bernasconi(SIB Swiss Institute of Bioinformatics)Jef De Schutter(KU Leuven)Bart Biesmans(KU Leuven)George Fountzilas(Aristotle University of Thessaloniki)Konstantine T. Kalogeras(Aristotle University of Thessaloniki)Vassiliki Kotoula(Hellenic Cooperative Oncology Group)Demetris PapamichaelPierre Laurent‐Puig(Délégation Paris 5)Frédérique Penault–Llorca(Centre Jean Perrin)Philippe Rougier(Hôpital Ambroise-Paré)Bruno Vincenzi(Università Campus Bio-Medico)Daniele Santini(Medica (Italy))Giuseppe Tonini(Medica (Italy))Federico Cappuzzo(Ospedale di Livorno)Milo FrattiniFrancesca MolinariPiercarlo Saletti(Ospedale San Giovanni Bellinzona)Sara De Dosso(Ospedale San Giovanni Bellinzona)Miriam Martini(University of Turin)Alberto Bardelli(University of Turin)Salvatore Siena(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)Andrea Sartore‐Bianchi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)Josep Tabernero(Vall d'Hebron Hospital Universitari)Teresa Macarulla(Vall d'Hebron Hospital Universitari)Frédéric Di Fiore(Inserm)Alice Gangloff(Inserm)Fortunato Ciardiello(University of Campania "Luigi Vanvitelli")Per Pfeiffer(Odense University Hospital)Camilla Qvortrup(Odense University Hospital)Tine Plato Hansen(Odense University Hospital)Eric Van Cutsem(KU Leuven)Hubert Piessevaux(Cliniques Universitaires Saint-Luc)Diether Lambrechts(KU Leuven)Mauro Delorenzi(SIB Swiss Institute of Bioinformatics)Sabine Tejpar(KU Leuven)

View via DOI Publisher page

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Lung Cancer Treatments and MutationsKRASCetuximabNeuroblastoma RAS viral oncogene homologMedicineColorectal cancerOncologyChemotherapyInternal medicinePanitumumabCancer research

MeSH terms

CetuximabAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedMutationGenes, rasRetrospective StudiesROC Curve